1. Home
  2. VAL vs ACLX Comparison

VAL vs ACLX Comparison

Compare VAL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$60.34

Market Cap

3.9B

Sector

Energy

ML Signal

HOLD

Logo Arcellx Inc.

ACLX

Arcellx Inc.

HOLD

Current Price

$68.70

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
ACLX
Founded
1975
2015
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.2B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
VAL
ACLX
Price
$60.34
$68.70
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$52.14
$115.50
AVG Volume (30 Days)
850.5K
1.1M
Earning Date
10-29-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.61
N/A
Revenue
$2,416,000,000.00
$35,898,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$302.49
P/E Ratio
$10.77
N/A
Revenue Growth
6.81
N/A
52 Week Low
$27.15
$47.86
52 Week High
$61.70
$94.07

Technical Indicators

Market Signals
Indicator
VAL
ACLX
Relative Strength Index (RSI) 63.14 33.01
Support Level $55.90 $66.00
Resistance Level $61.21 $75.03
Average True Range (ATR) 2.34 5.23
MACD 0.32 -1.69
Stochastic Oscillator 82.55 12.96

Price Performance

Historical Comparison
VAL
ACLX

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About ACLX Arcellx Inc.

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Share on Social Networks: